+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Natural Killer Cells Therapeutics Market by Therapeutics, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2018-2026

  • ID: 4844590
  • Report
  • July 2019
  • Region: Global
  • 217 pages
  • Allied Analytics LLP

Enquire about COVID-19 updates for this product.

Enquire Now
Natural killer (NK) cell is a component of innate immunity system that targets cancer cells, and can be used as a therapeutic agent. NK cells target the cells losing MHC-I in cancer, a phenotype that is similar to certain cells in immune-privileged sites whose milieus are separated from peripheral blood.

The global natural killer cell therapeutics market was valued at $1,402 million in 2018, and is projected to reach $5,096 million by 2026, registering a CAGR of 17.4% from 2019 to 2026.

The growth of the global natural killer cell therapeutics market is driven by rise in use of NK cells to treat cancer, infections, and liver diseases. Moreover, NK cells play vital role in tumor immune-surveillance, which has significantly boosted their adoption across the globe. In addition, rise in awareness among the population regarding various immunotherapies and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells propel the global natural killer cell therapeutics market growth. However, lack of specificity and poor in-vivo survival of the cells limit the growth of the market. Furthermore, higher costs associated with the therapies and adverse side effects are expected to hamper the market growth in the coming years. Conversely, significant surge in R&D activities toward development of immunotherapy in developing economies is anticipated to offer lucrative opportunities for the market.

The global natural killer cell therapeutics market is segmented based on therapeutics, application, end user, and region. Depending on therapeutics, the natural killer cells therapeutics market is classified into NK cell therapies and NK cell directed antibodies. By application, it is categorized into cancer, gastrointestinal diseases, immunoproliferative disorders, and others. On the basis of end user, it is segregated into hospitals, research centers & institutes, and others. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • This report entails a detailed quantitative analysis along with the current market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The global natural killer cell therapeutics market size and estimations are based on a comprehensive analysis of key developments.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
  • By Therapeutics
o NK Cell Therapies
o NK Cell Directed Antibodies
  • By Application
o Cancer
o Gastrointestinal Diseases
o Immunoproliferative Disorders
o Others
  • By End User
o Research Centers & Institutes
o Hospitals
o Others

By Region
o North America
  • U.S.
  • Canada
  • Mexico
o Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
o Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
o LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
The key players profiled in this report are as follows:
  • Affimed N.V.
  • Celgene Corporation
  • Fate Therapeutics
  • Fortress Biotech
  • Glycostem Therapeutics BV
  • Innate Pharma S.A.
  • Nantkwest Inc.
  • Nkarta Therapeutics, Inc.
  • NKT Therapeutics Inc.
  • Ziopharm Oncology Inc.
Note: Product cover images may vary from those shown
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in incidence of cancer across the globe
3.5.1.2. Increase in government expenditure on healthcare
3.5.1.3. Surge in awareness regarding immunotherapy
3.5.2. Restraints
3.5.2.1. High cost of cancer immunotherapy treatment
3.5.2.2. Stringent government regulations toward approval of immunotherapy
3.5.3. Opportunity
3.5.3.1. Surge in R&D activities toward the development of immunotherapy
3.6. Government regulatory scenerio
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.6.4. Thailand
3.6.5. Singapore
3.6.6. Malaysia
3.6.7. Mexico
3.6.8. Australia

CHAPTER 4: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY THERAPEUTICS
4.1. Overview
4.1.1. Market and forecast
4.2. Natural killer cell therapies
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.2.3.1. CNDO-109
4.2.3.2. oNKord
4.2.3.3. Natural Killer Cells
4.2.3.4. Others
4.3. NK cell-directed antibodies
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.3.1. MOGAMULIZUMAB
4.3.3.2. Lirilumab
4.3.3.3. AFM13
4.3.3.4. NKTT 120
4.3.3.5. Others

CHAPTER 5: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast, by region
5.2. Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Gastrointestinal diseases
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Immunoproliferative disorders
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast
5.5.2. Market analysis, by country

CHAPTER 6: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY END USER
6.1. Overview
6.1.1. Market and forecast
6.2. Research centers and institutes
6.2.1. Market and forecast, by region
6.2.2. Market analysis, by country
6.3. Hospitals and clinics
6.3.1. Market and forecast, by region
6.3.2. Market analysis, by country
6.4. Others
6.4.1. Market and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: NATURAL KILLER CELL THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by therapeutics
7.2.3. Market size and forecast, by application
7.2.4. Market size and forecast, by application
7.2.5. Market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by therapeutics
7.2.5.2. U.S. market size and forecast, by application
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by therapeutics
7.2.5.5. Canada market size and forecast, by application
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by therapeutics
7.2.5.8. Mexico market size and forecast, by application
7.2.5.9. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast, by therapeutics
7.3.3. Market size and forecast, by application
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. UK market size and forecast, by therapeutics
7.3.5.2. UK market size and forecast, by application
7.3.5.3. UK market size and forecast, by end user
7.3.5.4. Germany market size and forecast, by therapeutics
7.3.5.5. Germany market size and forecast, by application
7.3.5.6. Germany market size and forecast, by end user
7.3.5.7. France market size and forecast, by therapeutics
7.3.5.8. France market size and forecast, by application
7.3.5.9. France market size and forecast, by end user
7.3.5.10. Italy market size and forecast, by therapeutics
7.3.5.11. Italy market size and forecast, by application
7.3.5.12. Italy market size and forecast, by end user
7.3.5.13. Spain market size and forecast, by therapeutics
7.3.5.14. Spain market size and forecast, by application
7.3.5.15. Spain market size and forecast, by end user
7.3.5.16. Rest of Europe market size and forecast, by therapeutics
7.3.5.17. Rest of Europe market size and forecast, by application
7.3.5.18. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast, by therapeutics
7.4.3. Market size and forecast, by application
7.4.4. Market size and forecast, by end user
7.4.5. Market size and forecast, by country
7.4.5.1. Japan market size and forecast, by therapeutics
7.4.5.2. Japan market size and forecast, by application
7.4.5.3. Japan market size and forecast, by end user
7.4.5.4. China market size and forecast, by therapeutics
7.4.5.5. China market size and forecast, by application
7.4.5.6. China market size and forecast, by end user
7.4.5.7. Australia market size and forecast, by therapeutics
7.4.5.8. Australia market size and forecast, by application
7.4.5.9. Australia market size and forecast, by end user
7.4.5.10. India market size and forecast, by therapeutics
7.4.5.11. India market size and forecast, by application
7.4.5.12. India market size and forecast, by end user
7.4.5.13. Rest of Asia-Pacific market size and forecast, by therapeutics
7.4.5.14. Rest of Asia-Pacific market size and forecast, by application
7.4.5.15. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. Market size and forecast, by therapeutics
7.5.3. Market size and forecast, by application
7.5.4. Market size and forecast, by end user
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil market size and forecast, by therapeutics
7.5.5.2. Brazil market size and forecast, by application
7.5.5.3. Brazil market size and forecast, by end user
7.5.5.4. Saudi Arabia market size and forecast, by therapeutics
7.5.5.5. Saudi Arabia market size and forecast, by application
7.5.5.6. Saudi Arabia market size and forecast, by end user
7.5.5.7. South Africa market size and forecast, by therapeutics
7.5.5.8. South Africa market size and forecast, by application
7.5.5.9. South Africa market size and forecast, by end user
7.5.5.10. Rest of LAMEA market size and forecast, by therapeutics
7.5.5.11. Rest of LAMEA market size and forecast, by application
7.5.5.12. Rest of LAMEA market size and forecast, by end user

CHAPTER 8: COMPANY PROFILES
8.1. AFFIMED N.V.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. CELGENE CORPORATION
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. FATE THERAPEUTICS INC.
8.3.1. Company overview
8.3.2. Operating business segments
8.3.3. Product portfolio
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. FORTRESS BIOTECH
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. GLYCOSTEM THERAPEUTICS BV
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. INNATE PHARMA SA
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. NANTKWEST INC
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. NKARTA THERAPEUTICS, INC.
8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Product portfolio
8.8.4. Key strategic moves and developments
8.9. NKT THERAPEUTICS INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. ZIOPHARM ONCOLOGY INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
Note: Product cover images may vary from those shown
According to the report titled, 'Natural Killer Cells Therapeutics Market by Therapeutics, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2018-2026,' the global natural killer cells therapeutics market was valued at $1,402 million in 2018, and is projected to reach $5,096 million by 2026, registering a CAGR of 17.4% from 2019 to 2026. By application, the cancer segment accounted for a major share in 2018, and is expected to continue this trend during the forecast period, due to increase in adoption of NK cell therapies to treat various types of cancers such as acute myeloid leukemia, Hodgkin's lymphoma, hematologic malignancies, solid tumors, cutaneous T cell lymphoma, and head & neck cancer.

Natural killer cells are large granular lymphocytes that respond quickly to a pathological challenge. In addition, they are responsible for producing immunoregulatory cytokines. Moreover, they act as an important component of the innate immune system of a human to generate an immune response against malignancies and viral infections. In the past several years, these cells were being used in various molecular and combinational therapies, which increased the adoption of such treatments across the globe.

Rise in use of NK cells for the treatment of cancer, infections, and liver diseases has significantly boosted the adoption of natural killer therapeutics. In addition, rise in awareness among the population regarding various immunotherapies and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells propel the global natural killer cells therapeutics market growth.

By therapeutics, the natural killer cells therapeutics market is classified into NK cell therapies and NK cell directed antibodies. Based on application, the market is classified into cancer, gastrointestinal diseases, immunoproliferative disorders, and other. The cancer segment accounted for a major share in 2018 and is expected to experience highest growth during the forecast period, due to increase in adoption of NK cell therapies to treat various types of cancers such as acute myeloid leukemia, Hodgkin's lymphoma, hematologic malignancies, solid tumors, cutaneous T cell lymphoma, and head & neck cancer.

Depending on end user, the global natural killer cells therapeutics market is classified into hospitals, research centers & institutes, and others. The hospital segment is estimated to exhibit a CAGR of 17.7% during the forecast period, owing to surge in adoption of immunotherapy procedures using NK cells.

According to Onkar Sumant, Manager, Healthcare, “Natural killer cell therapeutics are majorly utilized in the healthcare sector, owing to increase in the prevalence of diseases, including cancer, gastrointestinal diseases, and others. Moreover, rise in government expenditure in the healthcare sector and increase in awareness of immunotherapy to treat various diseases are anticipated to boost the market growth. Furthermore, ongoing R&D activities in cancer immunotherapy to provide advanced features for patients for effective treatment significantly fuel the market growth.”

Key Findings of the Natural Killer Cells Therapeutics Market:

This report entails a detailed quantitative analysis along with the current global market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
The global natural killer cells therapeutics market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
The North America natural killer cells therapeutics market share accounted for the highest share in 2018 and is expected to continue its dominance throughout the forecast period, due to new product innovations. For instance, Fortress Biotech Inc. is involved in developing CNDO-109, a NK cell therapeutics, to treat acute myelogenous leukemia (AML). However, Asia-Pacific is anticipated to grow at the highest rate during the forecast period. This is attributed to increase in R&D activities toward the development of immunotherapies to treat various cancers and other disorders.
The global natural killer cells therapeutics market is highly competitive, and the prominent players in the market have adopted various strategies for garnering maximum market share. These include expansion of their geographical presence through collaborations and focus on R&D activities for NK cells.

Major players operating in the market include Affimed N.V., Celgene Corporation, Fate Therapeutics, Fortress Biotech, Glycostem Therapeutics BV, Innate Pharma S.A., Nantkwest Inc., Nkarta Therapeutics, Inc., NKT Therapeutics Inc., and Ziopharm Oncology Inc.
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll